Developing new ornithine decarboxylase inhibitors to prevent skin & colon cancer

开发新型鸟氨酸脱羧酶抑制剂预防皮肤病

• 批准号: 8434732
• 负责人: Zigang Dong
• 金额: $ 31.64万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8434732
• 关键词: Active Sites; Adverse effects; Affinity; Allosteric Site; Anabolism; Animal Experiments; Binding; Binding Sites; Biological Assay; Biological Models; Cancer Cell Growth; Chemoprevention; Chinese Traditional Medicine; Colon; Colon Carcinoma; Computational Biology; Computer Simulation; DL-alpha-Difluoromethylornithine; Data; Databases; Development; Docking; Dose; Enzymes; FDA approved; Human; Inflammation; Intraepithelial Neoplasia; Lead; Modeling; Mus; Ornithine Decarboxylase; Ornithine Decarboxylase Inhibitor; Pharmaceutical Preparations; Polyamines; Protein Binding; Research Personnel; Risk Factors; Site; Skin; Skin Cancer; Skin Carcinogenesis; Staging; Structure; Study models; System; Technology; Testing; Tissues; Toxic effect; Tumor Promoters; antibiotic G 418; cancer cell; cancer type; carcinogenesis; cell transformation; cell type; colon carcinogenesis; design; dimethylbenzanthracene; hearing impairment; in vivo; inhibitor/antagonist; mouse model; neoplastic; novel; prevent; public health relevance; screening; simulation; skin cancer prevention; small molecule; supercomputer; tumor growth; tumorigenesis

DESCRIPTION (provided by applicant): Increased polyamine synthesis and inflammation are associated with intraepithelial neoplasia, which are risk factors for various types of cancer development in humans. Ornithine decarboxylase (ODC) is highly expressed in many cancer cell types and promotes growth and tumor formation. Elevated ODC activity in carcinogenesis model systems and neoplastic tissues suggests that this enzyme is a valid target for chemoprevention. Difluoromethylornithine (DFMO) is an approved FDA drug that acts as an irreversible and specific ODC inhibitor, and reportedly prevents carcinogenesis, especially in the skin and colon. However, high doses of DFMO in humans are associated with various degrees of hearing loss. By using computational biology with the BlueGene/L supercomputer, we have found at least one small molecule allosteric inhibitor of ODC that is less toxic and more potent than DFMO in suppressing skin and colon carcinogenesis. In this application, we propose to use state of the art technologies to identify and test additional novel, nontoxic small molecule inhibitors of ODC. These approaches include determining binding, binding affinities, specific binding sites and resulting structural changes by computation simulation using the BlueGene/L Supercomputer and our newly acquired GPU system, and performing protein binding assays, cell transformation assays and in vivo animal experiments, including the 2-stage mouse skin carcinogenesis model and the APCmin mouse model. Through these studies, we will develop more effective agents targeting ODC with fewer side effects for the chemoprevention of skin cancer and colon cancer.

描述(由申请人提供)：多胺合成增加和炎症与上皮内瘤变有关，这是人类各种类型癌症发展的危险因素。鸟氨酸脱羧酶(ODC)在多种肿瘤细胞中高表达，促进肿瘤生长和形成。在致癌模型系统和肿瘤组织中升高的ODC活性表明该酶是化学预防的有效靶点。二氟甲基鸟氨酸(DFMO)是FDA批准的一种药物，作为一种不可逆转的特异性ODC抑制剂，据报道可防止癌症发生，特别是在皮肤和结肠。然而，人体内高剂量的DFMO与不同程度的听力损失有关。通过在Bluegene/L超级计算机上使用计算生物学，我们已经发现了至少一个ODC小分子变构抑制剂，它比DFMO毒性更低，抑制皮肤和结肠癌的作用更强。在这项应用中，我们建议使用最先进的技术来识别和测试其他新的、无毒的ODC小分子抑制剂。这些方法包括通过使用Bluegene/L超级计算机和我们新获得的图形处理系统进行计算模拟，确定结合、结合亲和力、特定结合部位和所导致的结构变化，以及进行蛋白质结合分析、细胞转化试验和体内动物实验，包括小鼠皮肤二阶段癌变模型和APCmin小鼠模型。通过这些研究，我们将开发更有效的针对ODC的药物，并减少副作用，用于皮肤癌和结肠癌的化学预防。